Galectin Therapeutics Inc. (GALT)

[thefamilyman]

I certainly agree with the first bullet. As to the third bullet, I had a little over half my shares in the warrants and I sold all my warrants the day after FX results were published. And I will be very pissed if they extend the term. Also I agree with your fourth bullet. That retention bonus continues to give off a pretty bad smell.

Maybe they should have fired Traber instead of Czirr but given the problems we are currently facing, which began before Czirr was canned; more likely they should have both been terminated.
1) There were no safety issues identified at 8mg so it is unbelievable that higher doses (and increased frequency of dosing) were not tested in our Phase 1.
2) And Traber is now saying that the FX trial was done primarily to test non-invasive diagnostic tools and that therefore the FX trial was not designed to advance GR-MD-02 with the FDA. That means the FX trial was an irresponsible waste of scarce company resources!

What I don't like:

• No testing of dosage over current highest dose. I don't understand the reasoning why this wasn't explored. What if efficacy increases further with a higher (or more frequent) dose? It's crazy to leave this door closed in my opinion.

• Melanoma trial could be our savior but the sample size is tiny and the market may not be impressed.

• I'm stuck at this point. Half my shares are in warrants that are so in the hole it isn't funny. For what I could get for my shares now, I'm willing to let it ride and take the loss if it should happen. Wish they could extend the term for the warrants until after CX results. (does that ever happen?)

• That retention bonus for two of the employees several months ago was, in my mind, pretty slimy. I should have listened to myself and not added after that or at least pulled some out just prior to FX results. Those bonuses indicate to me that the lackluster (or at the least unclear/uncertain) results of FX was expected.
- Darwinian